Paromomycin Sulfate

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 531030

CAS#: 1263-89-4 (sulfate)

Description: Paromomycin sulfate is an aminoglycoside antimicrobial agent derived from Streptomyces sp. AG-P 1441. Paromomycin likely induced resistance as confirmed by the expression of pathogenesis-related genes: PR-1, β-1,3-glucanase, chitinase, PR-4, peroxidase, and PR-10, which enhanced plant defense against P. capsici in chili pepper.

Price and Availability

Size Price Shipping out time Quantity
1g USD 190 2 Weeks
2g USD 350 2 Weeks
5g USD 750 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-07-15. Prices are subject to change without notice.

Paromomycin sulfate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 531030
Name: Paromomycin Sulfate
CAS#: 1263-89-4 (sulfate)
Chemical Formula: C23H47N5O18S
Exact Mass:
Molecular Weight: 713.706
Elemental Analysis: C, 38.71; H, 6.64; N, 9.81; O, 40.35; S, 4.49

Related CAS #: 1263-89-4 (sulfate)   7542-37-2 (free)  

Synonym: Paromomycin Sulfate, Paromomycin, FI 5853, FI-5853, FI5853, Humatin, Aminosidin

IUPAC/Chemical Name: (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-(((2R,3S,4R,5S)-5-(((1R,2R,3S,5R,6S)-3,5-diamino-2-(((2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)tetrahydro-2H-pyran-3,4-diol sulfate


InChi Code: InChI=1S/C23H45N5O14.H2O4S/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22;1-5(2,3)4/h5-23,29-36H,1-4,24-28H2;(H2,1,2,3,4)/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+;/m1./s1

SMILES Code: NC[C@@H]1O[C@@H]([C@@H]([C@H]([C@@H]1O)O)N)O[C@H]2[C@H]([C@@H](O[C@@H]2CO)O[C@@H]3[C@H]([C@@H](C[C@@H]([C@H]3O[C@H]4O[C@@H]([C@H]([C@@H]([C@H]4N)O)O)CO)N)N)O)O.OS(=O)(O)=O

Technical Data

White to off-white solid powder.

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Belhadj Hamida N, Boukthir A, Chlif S, Abdelhamid K, El Ahmadi Z, Louzir H, Mokni M, Morizot G, Buffet P, Smith PL, Kopydlowski KM, Kreishman-Deitrick M, Smith KS, Nielsen CJ, Ullman DR, Norwood JA, Thorne GD, McCarthy WF, Adams RC, Rice RM, Tang D, Berman J, Ransom J, Magill AJ, Grogl M. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013 Feb 7;368(6):524-32. doi: 10.1056/NEJMoa1202657. PubMed PMID: 23388004.

2: Ravis WR, Llanos-Cuentas A, Sosa N, Kreishman-Deitrick M, Kopydlowski KM, Nielsen C, Smith KS, Smith PL, Ransom JH, Lin YJ, Grogl M. Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis. Antimicrob Agents Chemother. 2013 Oct;57(10):4809-15. doi: 10.1128/AAC.00628-13. Epub 2013 Jul 22. PubMed PMID: 23877689; PubMed Central PMCID: PMC3811440.

3: Matsushita T, Chen W, Juskeviciene R, Teo Y, Shcherbakov D, Vasella A, Böttger EC, Crich D. Influence of 4'-O-Glycoside Constitution and Configuration on Ribosomal Selectivity of Paromomycin. J Am Chem Soc. 2015 Jun 24;137(24):7706-17. doi: 10.1021/jacs.5b02248. Epub 2015 Jun 12. PubMed PMID: 26024064.

4: Kempf I, Le Roux A, Perrin-Guyomard A, Mourand G, Le Devendec L, Bougeard S, Richez P, Le Pottier G, Eterradossi N. Effect of in-feed paromomycin supplementation on antimicrobial resistance of enteric bacteria in turkeys. Vet J. 2013 Nov;198(2):398-403. doi: 10.1016/j.tvjl.2013.05.030. Epub 2013 Jun 22. PubMed PMID: 23800604.

5: Balaraju K, Kim CJ, Park DJ, Nam KW, Zhang K, Sang MK, Park K. Paromomycin Derived from Streptomyces sp. AG-P 1441 Induces Resistance against Two Major Pathogens of Chili Pepper. J Microbiol Biotechnol. 2016 Sep 28;26(9):1542-50. doi: 10.4014/jmb.1603.03019. PubMed PMID: 27291677.

6: Das S, Rani M, Rabidas V, Pandey K, Sahoo GC, Das P. TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasis. Br J Pharmacol. 2014 Mar;171(5):1260-74. doi: 10.1111/bph.12530. PubMed PMID: 24670148; PubMed Central PMCID: PMC3952803.

7: Jamil KM, Haque R, Rahman R, Faiz MA, Bhuiyan AT, Kumar A, Hassan SM, Kelly H, Dhalaria P, Kochhar S, Desjeux P, Bhuiyan MA, Khan MM, Ghosh RS. Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis. 2015 Oct 23;9(10):e0004118. doi: 10.1371/journal.pntd.0004118. eCollection 2015. PubMed PMID: 26496648; PubMed Central PMCID: PMC4619770.

8: Brugués AP, Naveros BC, Calpena Campmany AC, Pastor PH, Saladrigas RF, Lizandra CR. Developing cutaneous applications of paromomycin entrapped in stimuli-sensitive block copolymer nanogel dispersions. Nanomedicine (Lond). 2015 Jan;10(2):227-40. doi: 10.2217/nnm.14.102. PubMed PMID: 25600968.

9: Berkov-Zrihen Y, Herzog IM, Feldman M, Sonn-Segev A, Roichman Y, Fridman M. Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections. Bioorg Med Chem. 2013 Jun 15;21(12):3624-31. doi: 10.1016/j.bmc.2013.03.046. Epub 2013 Apr 2. PubMed PMID: 23602621.

10: Kikuchi T, Koga M, Shimizu S, Miura T, Maruyama H, Kimura M. Efficacy and safety of paromomycin for treating amebiasis in Japan. Parasitol Int. 2013 Dec;62(6):497-501. doi: 10.1016/j.parint.2013.07.004. Epub 2013 Jul 12. PubMed PMID: 23850836.

11: Gaspar MM, Calado S, Pereira J, Ferronha H, Correia I, Castro H, Tomás AM, Cruz ME. Targeted delivery of paromomycin in murine infectious diseases through association to nano lipid systems. Nanomedicine. 2015 Oct;11(7):1851-60. doi: 10.1016/j.nano.2015.06.008. Epub 2015 Jul 11. PubMed PMID: 26169150.

12: Khan W, Kumar R, Singh S, Arora SK, Kumar N. Paromomycin-loaded albumin microspheres: efficacy and stability studies. Drug Test Anal. 2013 Jun;5(6):468-73. doi: 10.1002/dta.389. Epub 2012 Apr 18. PubMed PMID: 22514145.

13: Pujol-Brugués A, Calpena-Campmany AC, Riera-Lizandra C, Halbaut-Bellowa L, Clares-Naveros B. Development of a liquid chromatographic method for the quantification of paromomycin. Application to in vitro release and ex vivo permeation studies. Spectrochim Acta A Mol Biomol Spectrosc. 2014 Dec 10;133:657-62. doi: 10.1016/j.saa.2014.06.017. Epub 2014 Jun 14. PubMed PMID: 24992924.

14: Monge-Maillo B, López-Vélez R. Topical paromomycin and gentamicin for new world cutaneous leishmaniasis in Panama. Am J Trop Med Hyg. 2014 Jun;90(6):1191. doi: 10.4269/ajtmh.14-0040a. PubMed PMID: 24898981; PubMed Central PMCID: PMC4047753.

15: Atia AM, Mumina A, Tayler-Smith K, Boulle P, Alcoba G, Elhag MS, Alnour M, Shah S, Chappuis F, van Griensven J, Zachariah R. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan. Trop Med Int Health. 2015 Dec;20(12):1674-84. doi: 10.1111/tmi.12603. Epub 2015 Nov 11. PubMed PMID: 26427033.

16: Kim KH, An DR, Yoon HJ, Yang JK, Suh SW. Structure of Mycobacterium smegmatis Eis in complex with paromomycin. Acta Crystallogr F Struct Biol Commun. 2014 Sep;70(Pt 9):1173-9. doi: 10.1107/S2053230X14017385. Epub 2014 Aug 29. PubMed PMID: 25195887; PubMed Central PMCID: PMC4157414.

17: Khan W, Sharma SS, Kumar N. Bioanalytical method development, pharmacokinetics, and toxicity studies of paromomycin and paromomycin loaded in albumin microspheres. Drug Test Anal. 2013 Jun;5(6):453-60. doi: 10.1002/dta.339. Epub 2012 Mar 22. PubMed PMID: 22447374.

18: Davidson RN, den Boer M, Ritmeijer K. Paromomycin. Trans R Soc Trop Med Hyg. 2009 Jul;103(7):653-60. doi: 10.1016/j.trstmh.2008.09.008. Epub 2008 Oct 23. Review. PubMed PMID: 18947845.

19: Mével M, Sainlos M, Chatin B, Oudrhiri N, Hauchecorne M, Lambert O, Vigneron JP, Lehn P, Pitard B, Lehn JM. Paromomycin and neomycin B derived cationic lipids: synthesis and transfection studies. J Control Release. 2012 Mar 28;158(3):461-9. doi: 10.1016/j.jconrel.2011.12.019. Epub 2011 Dec 29. PubMed PMID: 22226775.

20: Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, Kirigi G, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tafes H, Mekonnen Y, Makonnen E, Ndegwa S, Sagaki P, Kimutai R, Kesusu J, Owiti R, Ellis S, Wasunna M. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl Trop Dis. 2012;6(6):e1674. doi: 10.1371/journal.pntd.0001674. Epub 2012 Jun 19. PubMed PMID: 22724029; PubMed Central PMCID: PMC3378617.